Luca Mezzadri; Wei Cong Tan; Xinxin Hao; Joan Quah; Abi Manesh S; Ya-Ting Chang; Anh T. K. Nguyen; Ying Ding; Suwatthiya Kitsaran; Hock Hin Chua; Sotharith Bory; Sasheela S L Ponnampalavanar; Siriluck Anunnatsiri; Mohd Zulfakar Mazlan; Azizullah Khan Dhiloo; Rongpong Plongla; Andrea Lay‐Hoon Kwa; Syed Faisal Mahmood; Arthur Dessi Roman; Louise Thwaites; Phan Vinh Tho; Sheng Ping Wu; Darunee Chotiprasitsakul; Ke Juin Wong; Hendri Wijaya; Cybéle Lara R. Abad; Muhammad Osama Rehman Khalid; Gazi Md. Salahuddin Mamun; Giri Shan Rajahram; Helio Gutierres; Huynh Ngoc Hon; Trần Văn Giang; Ngoc Thach Pham; Abhilasha Karkey; Samanmalee Gunasekara; Raph L Hamers; Robert Sinto; Inke N. D. Lubis; Minggui Wang; Merlin Moni; Po‐Yu Liu; Yonghong Xiao; Basudha Khanal; N. Lakshmi Priya; Yohei Doi; Hitoshi Honda; Bayaraa Baljin; Ulziijargal Gurav; Rosmonaliza Asli; Lowell Ling; Ashesh Dhungana; Li-Yang Hsu; David L. Paterson; Yin Mo; Jie Su; May Gee Ong; Kee Mee Tan; Amanda Wei Ping Ling; Shweta Rajkumar Singh; Siew Pei Ong; Jia Rhou Lai; Shiau Hui Diong; Suchart Booraphun; Ratiporn Bansong; Xun Ting Tiong; Alisa Hanum Arba'eni; Sophany Koy; Seanghuoy Ho; Helmi Bin Sulaiman; Soo Nee Tang; Pope Kosalaraksa; Zeti Norfidiyati Salmuna; Gabriel Zherong Yan; Ambreen Fatima; Suvaporn Anugulruengkitt; Sadia Shakoor; Cecilia C. Maramba Lazarte; Thi Kim Anh Nguyen; Jinlan Lin; Pitak Santanirand; Ruth Tsin En Cheng; Rina Yunita; Nicole Bernadette Terre; Madiha Hashmi; Md Ali Amin Nabin; Mohd Zaki Bin Mohd Zaili; Joshua Francis; H. Rogier van Doorn; Bidhya Sharma Sharma; Sumudu Withanage; Yulia R. Saharman; R. Lia Kusumawati; 秦晓华; Chithra Tomy; Chien-Hao Tseng; Ping Shen; Shyam Prasad Kafle; T. Palaniappan; Shogo Hanai; Damdindorj Boldbaatar; Mohamed Ibrahim Ali Alsaman; Khurelbaatar Nyamdavaa; Damdindorj Boldbaatar; Christopher Lai; Santosh Poudel

In reply to the Letter to Editor Regarding "Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study"

回复致编辑函，内容涉及“比较头孢他啶-阿维巴坦与其他适当抗菌疗法治疗土耳其OXA-48-或KPC-产酶肠杆菌科细菌感染的疗效：一项多中心回顾性匹配队列研究”。

International Journal of Antimicrobial Agents

IF4.6

2025-12-110

PRE

Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections

难治性铜绿假单胞菌感染的当前管理策略

Infectious Disease Clinics of North America

IF4.1

2025-12-080

PRE

Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE

评估阴性菌血流感染平台试验的可行性：BALANCE先锋期结果

BMJ OPEN

IF2.3

2025-12-040

The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial

胜率（Win Ratio）应通过其他胜率统计量进行补充，以提供相对和绝对治疗效应的全面图景：REPRIEVE试验的案例研究

CLINICAL INFECTIOUS DISEASES

IF7.3

2025-11-010

PRE

Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model

阿莫西林/舒巴坦与头孢他啶/阿维巴坦联用对产金属β-内酰胺酶的碳青霉烯耐药鲍曼不动杆菌：一种基于基因组信息的机制模型

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2025-11-010

OAAI

Convalescent plasma in hospitalised patients with COVID-19

康复期血浆在住院的COVID-19患者中

Internal Medicine Journal

IF1.5

2025-11-010

PRE

Mcquilten, Zoe; O'sullivan, Matthew V. N.; Purcell, Damien; Edler, Peta; Meagher, Niamh; Alcorn, Kylie; Bowen, Asha; Daly, James; Foo, Hong; Goulding, Susan; Gosbell, Iain; Hammond, Naomi; Hills, Thomas; Hoad, Veronica; Jha, Vivekanand; Lim, Lyn Li; Mcphee, Grace; Molton, James; Morpeth, Susan; Nguyen, Vi; Paterson, David; Rees, Megan; Roberts, Jason; Rogers, Benjamin A.; Stewart, Adam; Sasadeusz, Joe; Snelling, Thomas; Venkatesh, Balasubramanian; Wood, Erica; Davis, Joshua S.; Tong, Steven Y. C.; Price, David J.; Denholm, Justin T.

Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study

比较他唑巴坦西他肟与其它适当抗菌疗法在治疗产OXA-48或KPC肠杆菌科细菌感染中的效果：一项多中心回顾性匹配队列研究（土耳其）。

International Journal of Antimicrobial Agents

IF4.6

2025-10-270

OAAI

Ceftolozane/tazobactam in action: prescribing patterns, effectiveness, and healthcare utilization across seven countries

头孢洛林/他唑巴坦的应用：七个国家的处方模式、有效性和医疗资源利用情况

Journal of Global Antimicrobial Resistance

IF3.2

2025-10-240

OAAI

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

西他赛尔 versus 标准疗法用于医院获得性和 healthcare-associated 革兰氏阴性细菌血流感染（GAME CHANGER 试验）：一项开放标签、平行组、随机试验

The Lancet Infectious Diseases

IF31

2025-10-060

PRE

David L Paterson; Helmi Sulaiman; Po-Yu Liu; Mark D Chatfield; Mesut Yilmaz; Zeti Norfidiyati Salmuna; Mohd Zulfakar Mazlan; Siriluck Anunnatsiri; Rujipas Sirijatuphat; Darunee Chotiprasitsakul; David C Lye; Jyoti Somani; Shirin Kalimuddin; Abdullah T Aslan; Visanu Thamlikitkul; Yi-Tzu Lee; Ya-Sung Yang; Yi-Tsung Lin; Wan Nurliyana Wan Ramli; Chien-Hao Tseng; Sophia Archuleta; Yvonne Fu Zi Chan; Brian M Forde; Hugh Wright; Adam G Stewart; Kay A Ramsay; Weiping Ling; Vicki Rossi; Tiffany M Harris-Brown; Patrick N A Harris

Evaluating Clinical Impacts of Accessory Genome Elements: Escherichia coli Type III Secretion System 2 in Escherichia coli and Beyond!

评估附属基因组元件的临床影响：大肠杆菌（Escherichia coli）III型分泌系统2及其更广泛的应用！

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2025-10-010

PRE

Snapshot Genomic Surveillance Reveals Insights into Antimicrobial Resistance and Lineage Diversity of Uropathogens in Older Adults in Queensland

快照基因组监测揭示了对昆士兰州老年人尿路致病菌的抗菌药物耐药性和谱系多样性的见解。

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2025-10-010

OAAI